This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Calidi Biotherapeutics’s 8K filing here.
About Calidi Biotherapeutics
Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.
Featured Articles
- Five stocks we like better than Calidi Biotherapeutics
- Consumer Staples Stocks, Explained
- How Whitestone REIT is Transforming Sunbelt Retail Growth
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Top-Performing Non-Leveraged ETFs This Year
- How Can Investors Benefit From After-Hours Trading
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
